^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Matulane (procarbazine hydrochloride)

    Company:
    Leadiant Biosci
    Drug class:
    Alkylating agent
    Related drugs:
    3d
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Trial initiation date
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    1m
    CA082-1215: Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervous System Lymphoma (2025-521144-38-00)
    P1/2, N=31, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P1/2 trial
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride) • Actemra IV (tocilizumab)
    2ms
    ImproveCodel: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (clinicaltrials.gov)
    P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2031 --> Mar 2033 | Trial primary completion date: Mar 2031 --> Mar 2033
    Trial completion date • Trial primary completion date • HEOR
    |
    temozolomide • vincristine • lomustine • Matulane (procarbazine hydrochloride)
    2ms
    Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)
    P1/2, N=93, Completed, Memorial Sloan Kettering Cancer Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2026 | Trial primary completion date: Dec 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • Matulane (procarbazine hydrochloride)
    2ms
    Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma (clinicaltrials.gov)
    P3, N=305, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Oct 2025 --> Oct 2029 | Trial primary completion date: Oct 2025 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    temozolomide • vincristine • Matulane (procarbazine hydrochloride)
    4ms
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    6ms
    LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (clinicaltrials.gov)
    P1/2, N=118, Active, not recruiting, Institut Curie | Trial primary completion date: Aug 2025 --> Feb 2035
    Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Matulane (procarbazine hydrochloride)
    10ms
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    New P2 trial
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    10ms
    Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • vincristine • Matulane (procarbazine hydrochloride) • Velexbru (tirabrutinib)
    11ms
    Long-Term Remission of Recurrent Anaplastic Oligodendroglioma With WT-1-Specific CD8+ T-Cell Therapy: A Case Report. (PubMed, Brain Tumor Res Treat)
    After three cycles of procarbazine, lomustine, and vincristine chemotherapy, the residual tumor stabilized for 3 years...Recurrent anaplastic oligodendroglioma was confirmed, and adjuvant proton beam therapy and temozolomide chemotherapy were initiated...Continued regression led to complete remission-confirmed via MRI at the 15-month follow-up and sustained for 4.7 years. The patient's peripheral blood monocyte profiles and immune-associated cytokine analysis indicated T-cell activation following WT-1 sensitization.
    Journal
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor)
    |
    temozolomide • vincristine • lomustine • Matulane (procarbazine hydrochloride)
    11ms
    Chronic expanding hematoma following Gamma Knife irradiation for primary central nervous system lymphoma: illustrative case. (PubMed, J Neurosurg Case Lessons)
    In this patient, CEH could have resulted from VEGFR-1 expression due to GKRS. For a patient with slow lesion growth following GKRS for PCNSL, surgical removal should be considered, taking into account the possibility of CEH along with recurrence and radiation necrosis. https://thejns.org/doi/10.3171/CASE258.
    Journal
    |
    FLT1 (Fms-related tyrosine kinase 1)
    |
    Rituxan (rituximab) • methotrexate • vincristine • Matulane (procarbazine hydrochloride) • Velexbru (tirabrutinib)
    12ms
    LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (clinicaltrials.gov)
    P1/2, N=118, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | Trial completion date: Feb 2035 --> Aug 2035 | Trial primary completion date: Feb 2025 --> Aug 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Matulane (procarbazine hydrochloride)